Engineered Polymer-siRNA Polyplexes Provide Effective Treatment of Lung Inflammation.
暂无分享,去创建一个
Yağız Anıl Çiçek | V. Rotello | Jungkyun Im | Ritabrita Goswami | Taewon Jeon | H. Nagaraj | Michelle E. Farkas | F. Scaletti | D. Luther | Rui Huang | Yiwei Lee | Yuanchang Liu | J. Mager | Charlotte Bell | Javier A Mas-Rosario | J. Elia | Javier A. Mas-Rosario | Federica Scaletti | Yagiz Anil Cicek
[1] V. Rotello,et al. Cytosolic Protein Delivery Using Modular Biotin-Streptavidin Assembly of Nanocomposites. , 2022, ACS nano.
[2] Y. Lim,et al. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy. , 2022, Journal of controlled release : official journal of the Controlled Release Society.
[3] Ramezan Jafari,et al. Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management , 2021, Pneumonia.
[4] R. Langer,et al. Nucleic Acid Delivery for Therapeutic Applications. , 2021, Advanced drug delivery reviews.
[5] V. Rotello,et al. Supramolecular Arrangement of Protein in Nanoparticle Structures Predicts Nanoparticle Tropism for Neutrophils in Acute Lung Inflammation , 2021, Nature Nanotechnology.
[6] S. Sinha,et al. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections , 2021, Applied Microbiology and Biotechnology.
[7] Wei He,et al. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome , 2021, Acta Pharmaceutica Sinica B.
[8] V. Rotello,et al. Protein Delivery: If Your GFP (or Other Small Protein) Is in the Cytosol, It Will Also Be in the Nucleus. , 2021, Bioconjugate chemistry.
[9] N. Heuzé-Vourc’h,et al. Inhaled antibodies: formulations require specific development to overcome instability due to nebulization , 2021, Drug Delivery and Translational Research.
[10] K. Nikula,et al. BSTP Review of 12 Case Studies Discussing the Challenges, Pathology, Immunogenicity, and Mechanisms of Inhaled Biologics , 2021, Toxicologic pathology.
[11] K. Thanki,et al. Optimizing the Intracellular Delivery of Therapeutic Anti-inflammatory TNF-α siRNA to Activated Macrophages Using Lipidoid-Polymer Hybrid Nanoparticles , 2021, Frontiers in Bioengineering and Biotechnology.
[12] M. Cazzola,et al. Prospects for COPD treatment. , 2020, Current opinion in pharmacology.
[13] A. Fabro,et al. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians , 2020, Respiratory Medicine.
[14] D. Knoell,et al. Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges. , 2020, Journal of controlled release : official journal of the Controlled Release Society.
[15] M. Huber-Lang,et al. Inflammation, Thrombosis, and Destruction: The Three-Headed Cerberus of Trauma- and SARS-CoV-2-Induced ARDS , 2020, Frontiers in Immunology.
[16] L. Sechi,et al. Role of Infections in the Pathogenesis of Rheumatoid Arthritis: Focus on Mycobacteria , 2020, Microorganisms.
[17] L. Yeo,et al. Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study , 2020, Frontiers in Pharmacology.
[18] K. Tremblay,et al. Protein phosphatase 1 regulatory subunit 35 is required for ciliogenesis, notochord morphogenesis, and cell-cycle progression during murine development. , 2020, Developmental biology.
[19] Bo Hu,et al. Therapeutic siRNA: state of the art , 2020, Signal Transduction and Targeted Therapy.
[20] Anders Wittrup,et al. Imaging small molecule-induced endosomal escape of siRNA , 2020, Nature Communications.
[21] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[22] V. Rotello,et al. Direct Cytosolic Delivery of Proteins Through Co-Engineering of Proteins and Polymeric Delivery Vehicles. , 2020, Journal of the American Chemical Society.
[23] K. Deane,et al. Lung inflammation in the pathogenesis of rheumatoid arthritis , 2020, Immunological reviews.
[24] Xin Xu,et al. Efficient and targeted drug/siRNA co-delivery mediated by reversibly crosslinked polymersomes toward anti-inflammatory treatment of ulcerative colitis (UC) , 2019, Nano Research.
[25] P. Baatsen,et al. Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy. , 2018, Acta biomaterialia.
[26] V. Rotello,et al. Nanocapsule‐mediated cytosolic siRNA delivery for anti‐inflammatory treatment , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[27] William J Peveler,et al. A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array , 2018, Advanced materials.
[28] A. Khvorova,et al. Improving siRNA Delivery In Vivo Through Lipid Conjugation. , 2018, Nucleic acid therapeutics.
[29] Y. Taufiq-Yap,et al. The crucial roles of inflammatory mediators in inflammation: A review , 2018, Veterinary world.
[30] Gregg A. Duncan,et al. Fate of PEGylated antibody fragments following delivery to the lungs: Influence of delivery site, PEG size and lung inflammation , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[31] A. Choi,et al. Autophagy and inflammation in chronic respiratory disease , 2018, Autophagy.
[32] G. Aulakh. Neutrophils in the lung: “the first responders” , 2018, Cell and Tissue Research.
[33] Danhua Zhu,et al. Transporting carriers for intracellular targeting delivery via non-endocytic uptake pathways , 2017, Drug delivery.
[34] Andrew J. deMello,et al. High-Throughput Multi-parametric Imaging Flow Cytometry , 2017 .
[35] N. Gupta,et al. Immunological Aspect of Radiation-Induced Pneumonitis, Current Treatment Strategies, and Future Prospects , 2017, Front. Immunol..
[36] Yi-Wei Lee,et al. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing. , 2017, ACS nano.
[37] T. Mustelin,et al. Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation , 2017, Pharmacology & therapeutics.
[38] Kevin S. O’Fallon,et al. Characterization of neutrophils and macrophages from ex vivo-cultured murine bone marrow for morphologic maturation and functional responses by imaging flow cytometry. , 2017, Methods.
[39] S. Hobbs,et al. Beyond bronchitis: a review of the congenital and acquired abnormalities of the bronchus , 2016, Insights into Imaging.
[40] H. Derendorf,et al. Ciclesonide: A Pro-Soft Drug Approach for Mitigation of Side Effects of Inhaled Corticosteroids. , 2016, Journal of pharmaceutical sciences.
[41] L. Kong,et al. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model , 2016, Inflammation Research.
[42] M. Cazzola,et al. Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease , 2016, Drugs.
[43] S. Chaieb,et al. Cholesterol Depletion from a Ceramide/Cholesterol Mixed Monolayer: A Brewster Angle Microscope Study , 2016, Scientific Reports.
[44] A. Elhissi,et al. Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications , 2016, Medical Principles and Practice.
[45] Judy Lieberman,et al. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown , 2015, Nature Biotechnology.
[46] V. Rotello,et al. Direct cytosolic delivery of siRNA using nanoparticle-stabilized nanocapsules. , 2014, Angewandte Chemie.
[47] P. Diot,et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[48] N. McElvaney,et al. Therapeutic aerosol bioengineering of siRNA for the treatment of inflammatory lung disease by TNFα gene silencing in macrophages. , 2014, Molecular pharmaceutics.
[49] Robert Langer,et al. Degradable Lipid Nanoparticles with Predictable In Vivo siRNA Delivery Activity , 2014, Nature Communications.
[50] A. Blumenthal,et al. Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA , 2013, Molecular therapy. Nucleic acids.
[51] Robert Langer,et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling , 2013, Nature Biotechnology.
[52] S. Melgar,et al. Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[53] H. Magnussen,et al. The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers , 2013, European Respiratory Journal.
[54] S. Simões,et al. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. , 2012, Accounts of chemical research.
[55] Young Jik Kwon,et al. Efficient and targeted delivery of siRNA in vivo , 2010, The FEBS journal.
[56] Leslie Y Yeo,et al. Ultrasonic nebulization platforms for pulmonary drug delivery , 2010, Expert opinion on drug delivery.
[57] Jianzhu Chen,et al. A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA Delivery , 2009, Molecular pharmaceutics.
[58] Daniel G. Anderson,et al. Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.
[59] Judy Lieberman,et al. Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.
[60] T. Mukherjee,et al. Role of TNFα in pulmonary pathophysiology , 2006, Respiratory Research.